Published on 26 Mar 2023 on Simply Wall St. via Yahoo Finance
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold...
Key Insights
Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable to their trading decisionsA total of 6 investors have a majority stake in the company with 52% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
To get a sense of who is truly in control of Lyell Immunopharma, Inc. (NASDAQ:LYEL), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 47% to be precise, is institutions. Put another way, the group faces the maximum upside potential (or downside risk).